

## General Clinical Trial Disclaimer

The purpose of most clinical trials is to test new cancer treatments. Because potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects. The therapy for this clinical trial is intended for use by clinical physicians in controlled research studies, and the therapy may not prove to be more effective (and could be worse) than standard treatment.



*To see if you meet  
eligibility requirements,  
please consult your physician.*

Therion Biologics Corporation is a leader in developing therapeutic vaccines for treating cancer. The Company's goal is to generate safe and effective therapies that improve patients' quality of life and increase patient survival by stimulating the body's immune system to specifically attack cancer cells. For more information about Therion, please visit our website at [www.therionbio.com](http://www.therionbio.com)




76 Rogers Street  
Cambridge, MA 02142  
Phone: (617) 475-7500  
Fax: (617) 475-7501  
[www.therionbio.com](http://www.therionbio.com)

© Therion Biologics Corporation

## Prostate Cancer Vaccine

### Patient Brochure



*A leader in novel therapies for cancer*

# A Phase II Clinical Trial Investigating a Novel Prostate Cancer Vaccine - PROSTVAC-VF®

PROSTVAC-VF® is an investigational cancer vaccine. The vaccine is based on the theory that your body's immune system can be taught to fight cancer. PROSTVAC-VF directs the immune system to attack specific targets found on cancer cells. These targets are called Tumor Associated Antigens, or TAA's. This trial will help determine if this vaccine can help fight cancer.

This is a Phase II clinical trial evaluating the safety and effectiveness of PROSTVAC-VF in men with prostate cancer. The prostate cancer must no longer respond to hormone therapy and the patient must have signs of disease progression.

Patients will receive treatment, by injection, for about 6 months. Injections will be given every two weeks for the first six weeks and then monthly.

This trial is controlled, randomized and blinded, meaning that patients will be randomly assigned to receive either vaccine treatment or placebo (no medication) and will not know which treatment they are on. Placebo groups, also known as control groups, are often necessary in clinical trials to accurately determine whether a treatment is effective. If patients who received placebo get worse during the trial, they will be able to receive the vaccine.

## Technology Description

Therion's cancer vaccines are being developed for maximum therapeutic benefits using a combination of three elements: tumor-specific antigens, a proprietary combination of immunological co-stimulatory molecules called TRICOM™ that activate immune responses to tumor-associated antigens, and a set of virus vectors to effectively deliver the first two components to the patient's immune system.

**If you would like to know if you are eligible for this trial, please contact your physician.**